JAZZ Insider Trading

Insider Ownership Percentage: 4.20%
Insider Buying (Last 12 Months): $1,435,800.00
Insider Selling (Last 12 Months): $2,135,214.30

Jazz Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Jazz Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$369ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$5M$0$5MTotal Insider BuyingTotal Insider Selling

Jazz Pharmaceuticals Share Price & Price History

Current Price: $135.39
Price Change: Price Increase of +1.43 (1.07%)
As of 02/18/2025 05:00 PM ET

This chart shows the closing price history over time for JAZZ up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MarAprMayJunJulAugSepOctNovDecJanFeb$133.96Closing price on 02/17/25:

SEC Filings (Institutional Ownership Changes) for Jazz Pharmaceuticals (NASDAQ:JAZZ)

89.14% of Jazz Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at JAZZ by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$684Mbought$376MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1B-$500M$0$500M$1BTotal InflowsTotal Outflows
Jazz Pharmaceuticals logo
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
Read More on Jazz Pharmaceuticals

Today's Range

Now: $135.39
Low: $132.58
High: $135.70

50 Day Range

MA: $123.73
Low: $120.07
High: $136.82

52 Week Range

Now: $135.39
Low: $99.06
High: $138.27

Volume

557,486 shs

Average Volume

612,271 shs

Market Capitalization

$8.19 billion

P/E Ratio

19.07

Dividend Yield

N/A

Beta

0.56

Who are the company insiders with the largest holdings of Jazz Pharmaceuticals?

Jazz Pharmaceuticals' top insider shareholders include:
  1. Bruce C Cozadd (CEO)
  2. Neena M Patil (EVP)
  3. Renee D Gala (CFO)
  4. Kim Sablich (EVP)
  5. Philip L Johnson (CFO)
  6. Finbar Larkin (SVP)
  7. Kenneth W O'keefe (Director)
  8. Mary Elizabeth Henderson (SVP)
  9. Rick E Winningham (Director)
  10. Patricia Carr (CAO)
  11. Mark Douglas Smith (Director)
Learn More about top insider investors at Jazz Pharmaceuticals.

Who are the major institutional investors of Jazz Pharmaceuticals?

Jazz Pharmaceuticals' top institutional investors include:
  1. Vanguard Group Inc. — 9.98%
  2. LSV Asset Management — 4.19%
  3. Pacer Advisors Inc. — 3.66%
  4. Dimensional Fund Advisors LP — 3.37%
  5. Capital World Investors — 3.18%
  6. Ameriprise Financial Inc. — 3.02%
Learn More about top institutional investors of Jazz Pharmaceuticals stock.

Which major investors are selling Jazz Pharmaceuticals stock?

Within the previous quarter, JAZZ stock was sold by these institutional investors:
  1. Franklin Resources Inc.
  2. Polaris Capital Management LLC
  3. Woodline Partners LP
  4. Avidity Partners Management LP
  5. Point72 Asset Management L.P.
  6. Two Sigma Investments LP
  7. FMR LLC
  8. Perpetual Ltd
In the previous year, company insiders that have sold Jazz Pharmaceuticals company stock include:
  1. Bruce C Cozadd (CEO)
  2. Neena M Patil (EVP)
  3. Renee D Gala (CFO)
  4. Kim Sablich (EVP)
Learn More investors selling Jazz Pharmaceuticals stock.

Which major investors are buying Jazz Pharmaceuticals stock?

During the last quarter, JAZZ stock was acquired by institutional investors including:
  1. Fuller & Thaler Asset Management Inc.
  2. Darwin Global Management Ltd.
  3. Dimensional Fund Advisors LP
  4. Ameriprise Financial Inc.
  5. GMT Capital Corp
  6. Alyeska Investment Group L.P.
  7. Tri Locum Partners LP
  8. Pacer Advisors Inc.